^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A+C in Metastatic Lung Adenocarcinoma Cancer

    Excerpt:
    ...- EGFR was wild type, positive for ROS1 translocation or ALK translocation or MET amplification...
    Trial ID:
    NCT02946359
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Am J Transl Res
    Title:

    Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study

    Published date:
    03/15/2021
    Excerpt:
    ...NSCLC patients were treated with crizotinib (250 mg orally twice daily) and bevacizumab (7.5 mg/kg intravenous every three weeks)... There were 12 patients with ALK rearrangement, 1 patient with ROS-1 fusion, and 1 patient with c-MET amplification. The median follow-up time was 42.8 months. The median PFS and DOR of the patients with ALK rearrangement were 13.9 and 14.8 months respectively. Of the 12 patients, 7 gained partial response, 5 gained stable disease. The ORR and DCR were 58.3% and 100%.